I like your numbers but $100m revenue won't be achieved in 1-2 years IMO.
To reach that will take some time but if revenues increase substantially each quarter, the market will take notice and revalue this accordingly.
If they can get to $10-$20m revenue for 2017, they will be doing well IMO.
Take a look at Pharmaxis with its EMA approval for Bronchitol. Revenues aren't impressive.
Obv FDA approval will be huge if Clinuvel are successful in Europe.
Ann: SCENESSE Treatment in Europe-CUV.AX, page-4
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.84 |
Change
0.260(1.78%) |
Mkt cap ! $741.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $1.349M | 91.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 644 | $14.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.85 | 3489 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |